BioXcel and Takeda Partner to Repurpose Assets for Orphan Diseases
Takeda will gain access to and leverage BioXcel's Big Data Innovation Lab.
BRANFORD, Conn., April 9, 2015 (GLOBE NEWSWIRE) -- BioXcel Corporation, a global leader in providing cloud-based Pharma big data solutions for discovering novel products, announced today that it has entered into a partnership with Takeda Development Center Americas ("Takeda"), for the repurposing of assets across the gamut of rare diseases. Through this partnership, Takeda, a global research-based company with a focus on innovation in medicine for the health of people worldwide, will gain access to and leverage BioXcel's Big Data Innovation Lab - an integrated product discovery engine - and PharmGPS(TM) Orphan Disease Suite for drug discovery and repurposing.
Commenting on the partnership, BioXcel's CEO and Chairman, Vimal Mehta, Ph.D., said, "We are pleased that Takeda will leverage our expertise in rare and ultra rare diseases to support their innovation and portfolio expansion initiatives. Discovering novel applications for existing molecules is an increasingly attractive strategy to address patient needs, while capitalizing on previous investments and de-risking clinical development. Our Big Data Innovation Lab facilitates the repurposing of the most attractive candidates applicable to a given disease."